This study will examine the safety and efficacy of posaconazole in general use in Korea. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Study Type
OBSERVATIONAL
Enrollment
273
Posaconazole oral suspension prescribed according to the current local label
Number of participants with Serious Adverse Experiences
Time frame: During treatment and for 30 days following cessation of treatment
Number of participants with drug-related adverse experiences
Time frame: During treatment and for 30 days following cessation of treatment
Number of participants with unexpected drug-related adverse experiences
Time frame: During treatment and for 30 days following cessation of treatment
Number of participants with Non-Serious Adverse Experiences
Time frame: During treatment and for 30 days following cessation of treatment
Number of Participants with Responses of Improved, Not Improved, and Worsened
Time frame: After at least 14 days of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.